Show simple item record

dc.contributor.authorvan den Biggelaar, Robin H G A
dc.contributor.authorHoefnagel, Marcel H N
dc.contributor.authorVandebriel, Rob J
dc.contributor.authorSloots, Arjen
dc.contributor.authorHendriksen, Coenraad F M
dc.contributor.authorvan Eden, Willem
dc.contributor.authorRutten, Victor P M G
dc.contributor.authorJansen, Christine A
dc.date.accessioned2021-10-12T19:53:55Z
dc.date.available2021-10-12T19:53:55Z
dc.date.issued2021-09-22
dc.identifier.pmid34550041
dc.identifier.doi10.1080/14760584.2021.1977628
dc.identifier.urihttp://hdl.handle.net/10029/625316
dc.description.abstractBefore release, vaccine batches are assessed for quality to evaluate whether they meet the product specifications. Vaccine batch tests, in particular of inactivated and toxoid vaccines, still largely rely on in vivo methods. Improved vaccine production processes, ethical concerns, and suboptimal performance of some in vivo tests have led to the development of in vitro alternatives.en_US
dc.language.isoenen_US
dc.subject3rsen_US
dc.subjectalternativesen_US
dc.subjectanimal modelen_US
dc.subjectin vitroen_US
dc.subjectpotencyen_US
dc.subjectquality controlen_US
dc.subjectsafetyen_US
dc.subjectvaccinesen_US
dc.titleOvercoming scientific barriers in the transition from to non-animal batch testing of human and veterinary vaccines.en_US
dc.typeArticleen_US
dc.identifier.eissn1744-8395
dc.identifier.journalExpert Rev Vaccines 2021; 1-13 advance online publication (ahead of print)en_US
dc.source.journaltitleExpert review of vaccines
dc.source.beginpage1
dc.source.endpage13
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record